2018 ESMO Sarcoma and GIST Symposium: ‘take-home messages’ in soft tissue sarcoma

The 7th edition of the ‘ESMO Sarcoma and GIST Symposium’ was held in Milan in February 2018. For the first time, the Symposium brought together representatives from the European Reference Network on rare adult solid cancer (EURACAN) joined by sarcoma experts from the USA, Japan and patient advocacy groups, to share insights and discuss future directions in this rare condition. This commentary will summarise the highlights in soft tissue sarcomas.

[1]  J. Blay,et al.  Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. , 2018, The Lancet. Respiratory medicine.

[2]  A. Gronchi,et al.  Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  O. Naveiras,et al.  Comment on “MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma” , 2018, Haematologica.

[4]  S. Sleijfer,et al.  Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) , 2018, International journal of cancer.

[5]  O. Naveiras,et al.  Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma , 2018, Haematologica.

[6]  Steven J. M. Jones,et al.  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.

[7]  J. Crowley,et al.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[8]  P. Navarria,et al.  Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303 , 2017, Annals of Surgical Oncology.

[9]  Z. Duan,et al.  Therapeutic applications of histone deacetylase inhibitors in sarcoma. , 2017, Cancer treatment reviews.

[10]  Robin L. Jones,et al.  Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Rosenwald,et al.  Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases , 2017, Virchows Archiv.

[12]  Robin L. Jones,et al.  Treatment of retroperitoneal sarcoma: current standards and new developments , 2017, Current opinion in oncology.

[13]  J. Blay,et al.  An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  P. Rutkowski,et al.  Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  V. Miller,et al.  Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma. , 2017 .

[16]  I. Judson,et al.  Activity of cediranib in alveolar soft part sarcoma (ASPS) confirmed by CASPS (cediranib in ASPS), an international, randomised phase II trial (C2130/A12118). , 2017 .

[17]  J. Blay,et al.  Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study. , 2017 .

[18]  C. Lucchesi,et al.  Genetic landscape of soft-tissue sarcomas: Moving toward personalized medicine. , 2017 .

[19]  A. Gronchi,et al.  Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications , 2017, Therapeutic advances in medical oncology.

[20]  L. Mariani,et al.  Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis , 2017, Cancer journal.

[21]  Marian Harris,et al.  Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.

[22]  Robin L. Jones,et al.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Robin L. Jones,et al.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial , 2016, The Lancet.

[24]  F. Grosso,et al.  Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database , 2016, Annals of Surgical Oncology.

[25]  L. Qin,et al.  Efficacy of sorafenib in patients with desmoid-type fibromatosis. , 2016 .

[26]  J. Blay,et al.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.

[27]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[28]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[29]  I. Judson,et al.  Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience , 2015, Clinical Sarcoma Research.

[30]  A. D. Dei Tos,et al.  Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. , 2014, European journal of cancer.

[31]  R. Grimer.  On the effect of setting of a positive surgical margin in soft tissue sarcoma , 2014, Cancer.

[32]  K. S. Hall,et al.  Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  J. Larkin,et al.  A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. , 2014, Anticancer research.

[34]  J. Blay,et al.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.

[35]  A. D. Dei Tos,et al.  Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  A. D. Dei Tos,et al.  Sunitinib malate in solitary fibrous tumor (SFT). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[38]  A. D. Dei Tos,et al.  Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  L. Mariani,et al.  Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution , 2011, Annals of Surgical Oncology.

[40]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[41]  Robin L. Jones,et al.  Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. , 2009, European journal of cancer.

[42]  P. Casali,et al.  Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma , 2009, Clinical Cancer Research.

[43]  J. Blay,et al.  Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Jonathan J. Lewis,et al.  Histopathologic Type: An Independent Prognostic Factor in Primary Soft Tissue Sarcoma of the Extremity? , 2003, Annals of Surgical Oncology.

[45]  A. D. Tos.  Liposarcoma: new entities and evolving concepts. , 2000, Annals of diagnostic pathology.

[46]  T. Group,et al.  Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach From the Trans-Atlantic RPS Working Group , 2014, Annals of Surgical Oncology.

[47]  A. D. Dei Tos.  Liposarcoma: new entities and evolving concepts. , 2000, Annals of diagnostic pathology.